Brief: Ligand Reports Q3 2024 Financial Results And Raises 2024 Guidance
07/11/2024 12:21
Nov 7 (Reuters) - Ligand Pharmaceuticals Inc LGND.O :
* LIGAND REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND
RAISES
2024 GUIDANCE
* LIGAND PHARMACEUTICALS INC: 2024 FULL YEAR REVENUE
GUIDANCE
INCREASED TO $160 MILLION - $165 MILLION
* LIGAND PHARMACEUTICALS INC OUTLOOK 2024 CORE ADJUSTED
EARNINGS
PER DILUTED SHARE $5.50 - $5.70
Source text: ID:nBw6xl2HMa
Further company coverage: LGND.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan